Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged.

Deadlines:

  • Letter of Intent Due Date(s):30 days prior to the application due date
  • AIDS Application Due Date(s): Aug. 3, 2022

RFA-AI-22-022 Expiration Date Aug. 4, 2022

Agency Website

Amount Description

 

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Environmental & Life Sciences
Interdisciplinary
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

August 3, 2022